{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Ellipticines : Questions médicales les plus fréquentes",
"headline": "Ellipticines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Ellipticines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-02",
"dateModified": "2025-03-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Ellipticines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Carbazoles",
"url": "https://questionsmedicales.fr/mesh/D002227",
"about": {
"@type": "MedicalCondition",
"name": "Carbazoles",
"code": {
"@type": "MedicalCode",
"code": "D002227",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.300.148"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Ellipticines",
"alternateName": "Ellipticines",
"code": {
"@type": "MedicalCode",
"code": "D004611",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elaine C O'Sullivan",
"url": "https://questionsmedicales.fr/author/Elaine%20C%20O%27Sullivan",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Analytical and Biological Chemistry Research Facility, University College Cork, Western Road, Cork T12 K8AF, Ireland."
}
},
{
"@type": "Person",
"name": "Florence O McCarthy",
"url": "https://questionsmedicales.fr/author/Florence%20O%20McCarthy",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry and Analytical and Biological Chemistry Research Facility, University College Cork, Western Road, Cork T12 K8AF, Ireland."
}
},
{
"@type": "Person",
"name": "Hao Lu",
"url": "https://questionsmedicales.fr/author/Hao%20Lu",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China."
}
},
{
"@type": "Person",
"name": "Manli Liu",
"url": "https://questionsmedicales.fr/author/Manli%20Liu",
"affiliation": {
"@type": "Organization",
"name": "Hubei Biopesticide Engineering Research Centre, Hubei Academy of Agricultural Sciences, Wuhan, China."
}
},
{
"@type": "Person",
"name": "Wenjia Lu",
"url": "https://questionsmedicales.fr/author/Wenjia%20Lu",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors.",
"datePublished": "2023-02-12",
"url": "https://questionsmedicales.fr/article/36660902",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/cpt.2851"
}
},
{
"@type": "ScholarlyArticle",
"name": "The case for complement component 5 as a target in neurodegenerative disease.",
"datePublished": "2023-02-17",
"url": "https://questionsmedicales.fr/article/36786123",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14728222.2023.2177532"
}
},
{
"@type": "ScholarlyArticle",
"name": "Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.",
"datePublished": "2023-08-09",
"url": "https://questionsmedicales.fr/article/37622108",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1213920"
}
},
{
"@type": "ScholarlyArticle",
"name": "Eculizumab treatment alters the proteometabolome beyond the inhibition of complement.",
"datePublished": "2023-07-10",
"url": "https://questionsmedicales.fr/article/37227781",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1172/jci.insight.169135"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Role of Complement in Autoimmune Disease-Associated Thrombotic Microangiopathy and the Potential for Therapeutics.",
"datePublished": "2023-01-15",
"url": "https://questionsmedicales.fr/article/36642429",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3899/jrheum.220752"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérocycliques 3 noyaux",
"item": "https://questionsmedicales.fr/mesh/D006575"
},
{
"@type": "ListItem",
"position": 5,
"name": "Carbazoles",
"item": "https://questionsmedicales.fr/mesh/D002227"
},
{
"@type": "ListItem",
"position": 6,
"name": "Ellipticines",
"item": "https://questionsmedicales.fr/mesh/D004611"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Ellipticines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Ellipticines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-16",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Ellipticines",
"description": "Comment diagnostiquer une tumeur sensible aux ellipticines ?\nQuels tests sont utilisés pour évaluer l'efficacité des ellipticines ?\nLes ellipticines sont-elles utilisées pour tous les types de cancer ?\nQuels signes cliniques indiquent un traitement par ellipticines ?\nComment évaluer les effets secondaires des ellipticines ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Complement+C5&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Ellipticines",
"description": "Quels symptômes peuvent indiquer un cancer traité par ellipticines ?\nLes ellipticines provoquent-elles des effets secondaires ?\nComment reconnaître une réaction allergique aux ellipticines ?\nLes ellipticines affectent-elles le système immunitaire ?\nQuels signes indiquent une toxicité des ellipticines ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Complement+C5&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Ellipticines",
"description": "Peut-on prévenir les cancers traités par ellipticines ?\nQuels facteurs de risque sont associés aux cancers traités par ellipticines ?\nLes vaccinations peuvent-elles aider à prévenir le cancer ?\nComment un mode de vie sain influence-t-il le risque de cancer ?\nLes examens de santé réguliers sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Complement+C5&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Ellipticines",
"description": "Comment les ellipticines sont-elles administrées ?\nLes ellipticines sont-elles utilisées en monothérapie ?\nQuel est le mécanisme d'action des ellipticines ?\nQuelles sont les alternatives aux ellipticines ?\nComment surveiller l'efficacité du traitement par ellipticines ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Complement+C5&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Ellipticines",
"description": "Quelles complications peuvent survenir avec les ellipticines ?\nLes ellipticines peuvent-elles causer des dommages aux organes ?\nComment gérer les effets secondaires graves des ellipticines ?\nLes ellipticines augmentent-elles le risque de récidive du cancer ?\nQuels sont les risques de surdosage d'ellipticines ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Complement+C5&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Ellipticines",
"description": "Quels sont les principaux facteurs de risque pour les cancers traités par ellipticines ?\nL'hérédité joue-t-elle un rôle dans le risque de cancer ?\nL'alimentation influence-t-elle le risque de cancer ?\nLe stress est-il un facteur de risque pour le cancer ?\nLes infections virales augmentent-elles le risque de cancer ?",
"url": "https://questionsmedicales.fr/mesh/D004611?mesh_terms=Complement+C5&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une tumeur sensible aux ellipticines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic est établi par biopsie et analyses histopathologiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'efficacité des ellipticines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'imagerie comme l'IRM et des marqueurs tumoraux sont utilisés."
}
},
{
"@type": "Question",
"name": "Les ellipticines sont-elles utilisées pour tous les types de cancer ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elles sont principalement efficaces contre certains cancers comme le cancer du poumon."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent un traitement par ellipticines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de progression tumorale ou de résistance aux autres traitements peuvent indiquer leur utilisation."
}
},
{
"@type": "Question",
"name": "Comment évaluer les effets secondaires des ellipticines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires sont évalués par des examens cliniques et des questionnaires de qualité de vie."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un cancer traité par ellipticines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleur, fatigue, perte de poids et changements d'appétit."
}
},
{
"@type": "Question",
"name": "Les ellipticines provoquent-elles des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent causer nausées, vomissements, et troubles hématologiques."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique aux ellipticines ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent indiquer une allergie."
}
},
{
"@type": "Question",
"name": "Les ellipticines affectent-elles le système immunitaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner une immunosuppression, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une toxicité des ellipticines ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes de toxicité incluent fatigue extrême, saignements inhabituels et jaunisse."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les cancers traités par ellipticines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mesures préventives incluent un mode de vie sain et des dépistages réguliers."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux cancers traités par ellipticines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le tabagisme, l'exposition à des agents carcinogènes et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles aider à prévenir le cancer ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines vaccinations, comme celles contre le HPV, peuvent réduire le risque de cancer."
}
},
{
"@type": "Question",
"name": "Comment un mode de vie sain influence-t-il le risque de cancer ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant alimentation équilibrée et exercice, peut réduire le risque."
}
},
{
"@type": "Question",
"name": "Les examens de santé réguliers sont-ils importants ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de détecter précocement des anomalies et d'initier un traitement rapide."
}
},
{
"@type": "Question",
"name": "Comment les ellipticines sont-elles administrées ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont généralement administrées par voie intraveineuse ou orale."
}
},
{
"@type": "Question",
"name": "Les ellipticines sont-elles utilisées en monothérapie ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être utilisées seules ou en association avec d'autres traitements anticancéreux."
}
},
{
"@type": "Question",
"name": "Quel est le mécanisme d'action des ellipticines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles agissent en interférant avec l'ADN des cellules cancéreuses, inhibant leur prolifération."
}
},
{
"@type": "Question",
"name": "Quelles sont les alternatives aux ellipticines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les alternatives incluent d'autres chimiothérapies, thérapies ciblées et immunothérapies."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement par ellipticines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est surveillée par des examens d'imagerie et des bilans sanguins réguliers."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les ellipticines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections, des saignements et des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les ellipticines peuvent-elles causer des dommages aux organes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des toxicités hépatiques et rénales, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires graves des ellipticines ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut l'ajustement de la dose, l'utilisation de médicaments symptomatiques et le suivi."
}
},
{
"@type": "Question",
"name": "Les ellipticines augmentent-elles le risque de récidive du cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire le risque de récidive, mais un suivi régulier est essentiel."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de surdosage d'ellipticines ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le surdosage peut entraîner des effets toxiques graves, nécessitant une intervention médicale immédiate."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque pour les cancers traités par ellipticines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent le tabagisme, l'exposition à des produits chimiques et l'âge."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans le risque de cancer ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer augmentent le risque de développer certaines tumeurs."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le risque de cancer ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en fruits et légumes peut réduire le risque de certains cancers."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque pour le cancer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Bien que le stress ne soit pas un facteur direct, il peut affecter le système immunitaire."
}
},
{
"@type": "Question",
"name": "Les infections virales augmentent-elles le risque de cancer ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections virales, comme le HPV, sont liées à un risque accru de cancer."
}
}
]
}
]
}
Drug-target-drug complexes (DTDCs) are phenomena newly observed in patients who switch from the complement component 5 (C5) inhibitor eculizumab to crovalimab, a novel, anti-C5 antibody in development...
Complement-based drug discovery is undergoing a renaissance, empowered by new advances in structural biology, complement biology and drug development. Certain components of the complement pathway, par...
We will discuss the evidence supporting C5 as a target in neurodegenerative disease, along with the current progress in developing different classes of C5 inhibitors and the gaps in knowledge that wil...
Validation of C5 as a therapeutic target for neurodegenerative disease would represent a major step forward for complement therapeutics research and has the potential to furnish disease-modifying drug...
The complement system is a key component of the innate immune system, and its aberrant activation underlies the pathophysiology of various diseases. Zilucoplan is a macrocyclic peptide that binds and ...
The interaction of zilucoplan with C5, including for clinical C5 R885 variants, was investigated using surface plasmon resonance (SPR), hemolysis assays, and ELISA. The interference of C5b6 formation ...
Zilucoplan specifically bound human complement C5 with high affinity, competitively inhibited the binding of C5 to C3b, and blocked C5 cleavage by C5 convertases and the assembly of the cytolytic memb...
Our findings demonstrate that zilucoplan uses a dual mode of action to potently inhibit the activation of C5 and terminal complement pathway including wild-type and clinical R885 variants that do not ...
Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis (MG). However, a deeper understanding of complement modulation in the human system is required to imp...
The complement system is a tightly regulated, cascading protein network representing a key component linking the innate and humoral immune systems. However, if misdirected or dysregulated, it can be s...
Over the last decade, perspectives on the complement system in the context of cancer have shifted, with complement proteins now implicated in many of the hallmarks of cancer. Systemically, the generat...
Over a century after the discovery of the complement system, the first complement therapeutic was approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). It was a long-acting monoclon...
The thrombin generation assay (TGA) evaluates the potential of plasma to generate thrombin over time, providing a global picture of an individual's hemostatic balance....
This study aimed to identify novel biological determinants of thrombin generation using a multi-omics approach....
Associations between TGA parameters and plasma levels of 377 antibodies targeting 236 candidate proteins for cardiovascular risk were tested using multiple linear regression analysis in 770 individual...
Eighteen proteins were associated (p<1.33x10-4) with at least three TGA parameters in MARTHA, among which 13 demonstrated a similar pattern of associations in EFS-AM. Complement proteins C5 and C9 had...
This study identified complement proteins C5 and C9 as potential determinants of thrombin generation. Further studies are warranted to establish causality and elucidate the underlying mechanisms....
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease characterized by damage to the alveolar epithelium, leading to fibrosis and excessive accumulation of extracellul...
African Trypanosomes have developed elaborate mechanisms to escape the adaptive immune response, but little is known about complement evasion particularly at the early stage of infection. Here we show...